NRx Pharmaceuticals

NRx is a clinical-stage pharmaceutical company that is developing ZYESAMI (aviptadil acetate) for COVID-19 and NRX-101, the first oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder.



Post IPO Equity




Org chart

Stephen Willard
CEO & Director
Jonathan C. Javitt
Founder & Chief Scientist
Rick Panicucci
Chief Technology Officer
Seth Van Voorhees
Chief Financial Officer
Dennis K. McBride
Chief Strategy Officer & Senior Scientist
Matthew Duffy
Chief Business Officer
Robert Besthof
Head of Operations & Chief Commercial Officer
Philip T. Lavin
Chief Methodologist
Michael Kunz
General Counsel & Corporate Secretary
Martin Brecher
Medical Director
Two candidates
The Org
helps you hire
great candidates
It takes less than ten minutes to set up your company page.
It’s free to use - try it out today.